These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats. Akel G, Canal P, Mockey E, Vandevoorde E, Laurent F, Soula G. J Pharmacol; 1983; 14(1):67-77. PubMed ID: 6834852 [Abstract] [Full Text] [Related]
3. The penetration of misonidazole and desmethylmisonidazole into brain tumours and other central nervous system tissues in man. Bleehen NM, Grant RM, Jones DH, Roberts JT, Workman P, Gleave JR, Hardy DG, Holmes AE. Br J Radiol; 1983 Nov; 56(671):859-63. PubMed ID: 6626877 [Abstract] [Full Text] [Related]
5. Nonlinear pharmacokinetics of misonidazole and desmethylmisonidazole in the isolated perfused rat liver. McManus ME, Monks A, Collins JM, White R, Strong JM. J Pharmacol Exp Ther; 1981 Dec; 219(3):669-74. PubMed ID: 7299690 [Abstract] [Full Text] [Related]
6. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole. White R, Workman P, Owen L. Int J Radiat Oncol Biol Phys; 1982 Dec; 8(3-4):473-6. PubMed ID: 7107369 [Abstract] [Full Text] [Related]
12. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study. Saunders MI, Dische S, Fermont D, Bishop A, Lenox-Smith I, Allen JG, Malcolm SL. Br J Cancer; 1982 Nov; 46(5):706-10. PubMed ID: 7171452 [Abstract] [Full Text] [Related]
13. Pharmacokinetics of hypoxic cell radiosensitizers: a review. Workman P. Cancer Clin Trials; 1980 Nov; 3(3):237-51. PubMed ID: 7438321 [Abstract] [Full Text] [Related]
14. Distribution of misonidazole in human tumours and normal tissues. Ash DV, Smith MR, Bugden RD. Br J Cancer; 1979 May; 39(5):503-9. PubMed ID: 486305 [Abstract] [Full Text] [Related]
15. Kinetic aspects of misonidazole and its major metabolite in radiotherapy. Meering PG, Gonzalez DG, Maes RA, van Peperzeel HA. Hum Toxicol; 1985 Jul; 4(4):425-34. PubMed ID: 4018823 [Abstract] [Full Text] [Related]
16. A drug for improved radiosensitization in radiotherapy. Dische S, Fowler JF, Saunders MI, Stratford MR, Anderson P, Minchinton AI, Lee ME. Br J Cancer; 1980 Jul; 42(1):153-5. PubMed ID: 7426325 [No Abstract] [Full Text] [Related]
17. The effect of vitamin B6 on the neurotoxicity and pharmacology of desmethylmisonidazole and misonidazole: clinical and laboratory studies. Coleman CN, Hirst VK, Brown DM, Halsey J. Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1381-6. PubMed ID: 6469761 [Abstract] [Full Text] [Related]
18. A comparison of the tumour concentrations obtainable with misonidazole and Ro 03-8799. Dische S, Saunders MI, Bennett MH, Dunphy EP, Des Rochers C, Stratford MR, Minchinton AI, Wardman P. Br J Radiol; 1986 Sep; 59(705):911-7. PubMed ID: 3756388 [Abstract] [Full Text] [Related]
19. Initial pharmacology and toxicology of intravenous desmethylmisonidazole. Coleman CN, Wasserman TH, Phillips TL, Strong JM, Urtasun RC, Schwade JG, Johnson RJ, Zagars G. Int J Radiat Oncol Biol Phys; 1982 Sep; 8(3-4):371-5. PubMed ID: 7107354 [Abstract] [Full Text] [Related]
20. The penetration of misonidazole into a mature structural cartilage. Langler AJ, Bugden RD, Gibson P. Br J Cancer; 1982 Feb; 45(2):282-5. PubMed ID: 7059476 [Abstract] [Full Text] [Related] Page: [Next] [New Search]